Epstein-Barr Virus- (EBV-) immortalized Lymphoblastoid Cell Lines (LCLs) express high level of CD23 but low CD27 to support their growth by Yap, Hooi Yeen * et al.
Research Article
Epstein-Barr Virus- (EBV-) Immortalized Lymphoblastoid
Cell Lines (LCLs) Express High Level of CD23 but Low CD27 to
Support Their Growth
Hooi-Yeen Yap,1 Thin-Sam Siow,2 Sook-Khuan Chow,3 and Sin-Yeang Teow 1
1Department of Medical Sciences, School of Healthcare and Medical Sciences, Sunway University, Jalan Universiti,
Bandar Sunway, 47500 Subang Jaya, Selangor Darul Ehsan, Malaysia
2Department of Biological Sciences, School of Science and Technology, Sunway University, Jalan Universiti,
Bandar Sunway, 47500 Subang Jaya, Selangor Darul Ehsan, Malaysia
3Sunway Medical Centre, Jalan Lagoon Selatan, Bandar Sunway, 47500 Subang Jaya, Selangor Darul Ehsan, Malaysia
Correspondence should be addressed to Sin-Yeang Teow; ronaldt@sunway.edu.my
Received 30 November 2018; Revised 20 February 2019; Accepted 6 March 2019; Published 28 March 2019
Academic Editor: Finn S. Pedersen
Copyright © 2019 Hooi-Yeen Yap et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Epstein-Barr virus (EBV) is one of the common human herpesvirus types in the world. EBV is known to infect more than
95% of adults in the world. The virus mainly infects B lymphocytes and could immortalize and transform the cells into EBV-
bearing lymphoblastoid cell lines (LCLs). Limited studies have been focused on characterizing the surface marker expression of
the immortalized LCLs. This study demonstrates the generation of 15 LCLs from sixteen rheumatoid arthritis (RA) patients and a
healthy volunteer using B95-8 marmoset-derived EBV. The success rate of LCL generation was 88.23%. All CD19+ LCLs expressed
CD23 (16.94-58.9%) and CD27 (15.74-80.89%) on cell surface. Our data demonstrated two distinct categories of LCLs (fast- and
slow-growing) (p<0.05) based on their doubling time. The slow-growing LCLs showed lower CD23 level (35.28%) compared to
fast-growing LCLs (42.39%). In contrast, the slow-growing LCLs showed higher percentage in both CD27 alone and CD23+CD27+
in combination. Overall, these findings may suggest the correlations of cellular CD23 and CD27 expression with the proliferation
rate of the generated LCLs. Increase expression of CD23 may play a role in EBV immortalization of B-cells and the growth and
maintenance of the EBV-transformed LCLs while CD27 expression might have inhibitory effects on LCL proliferation. Further
investigations are warranted to these speculations.
1. Introduction
Epstein-Barr virus (EBV) has infected more than 95% adults
globally [1]. EBV mainly targets and infects B-cells followed
by epithelial cells and, to a lesser extent, CD4 T-cells [2].
Infectious virions are produced following the lytic replication
in B-cells and epithelial cells. After the lytic cycle, EBV
latency follows and persists in the infected B-cells for the
rest of the individual’s life [2]. EBV mainly causes infectious
mononucleosis and it is also closely associated with both
lymphoid and epithelial malignancies such as Burkitt’s lym-
phoma, Hodgkin’s lymphoma, nasopharyngeal carcinoma,
and gastric cancer [3].
EBV infects B-cells and could immortalize the B-cells
and form long-termgrowing LCLswhich consistently express
the viruses [4]. This method has been used in laboratories
to immortalize certain human blood-derived B-cells which
can be later on used as a culture model for various studies
including large-scale drug library screening, vaccine study,
and high throughput biological studies [5, 6]. Amongst all,
EBV produced from B95-8, a marmoset cell line, appears
to be the most common and potent EBV source for B-
cell immortalization. In the past decades, researchers have
put in effort to improve the immortalization method and
its efficiency [7]. Recently, it has been shown that with a
minor modification, LCLs could be generated from a small
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volume of peripheral blood as low as 0.1mL [4].This finding is
particularly useful under a circumstance in which the sample
volume is limited.
Previous studies have reported that immune cells par-
ticularly B-cells and their subsets play pivotal role in the
pathogenesis of RA [8, 9]. Despite the success of EBV
immortalization of B-cells, little has been done on the
characterization of LCLs and its comparisonwith the parental
B-cells. In this study, we demonstrated that EBV could
efficiently immortalize B-cells from RA patients’ peripheral
blood and form LCLs. We then examined the expression
levels of several B-cells subpopulation markers including
CD23 and CD27 in both LCLs and their parental B-cells.
These B-cell subpopulations have been previously associated
with the clinical presentation of RA patients. For instance,
elevated B-cells expressing CD23 have been detected in RA
patients and they could be blocked bymonoclonal antibodies
[10]. Similarly, increased amount of CD27+IgD− memory B-
cells was also readily detected in patients with active RA [11].
On the other hand, Hu and coworkers demonstrated that
CD27+ B-cells negatively correlated with the disease activity
of RA and were found to be impaired in the patients [12].
In this study, we sought to evaluate the expression level
of CD23 and/or CD27 of B-cells from the PBMCs and LCLs
derived fromRApatients.We also investigated the expression
level of CD23 and CD27 in regard to the cellular growth of
LCLs.
2. Materials and Methods
2.1. Patient Samples. 5mL of peripheral blood from sixteen
RA patients (Table 1) was collected from Sunway Medical
Centre, Malaysia, under an ethical approval code of 011/2017/
ER. PBMCswere isolated using Ficoll-Paque (GEHealthcare)
method. Briefly, the blood collected in EDTA tube was
diluted 1 to 1 with sterile phosphate-buffered saline (PBS)
and layered onto Ficoll-Paque solution in a fresh centrifuge
tube. The tube was centrifuged at 400 xg for 40 minutes at
room temperature with low acceleration and ‘brake off ’. The
top layer which is the plasma was collected and aliquoted
before storing at -80∘C. The buffy coat containing PBMCs
was collected using 3mL Pasteur pipette and transferred to
a fresh centrifuge tube. The cells were washed twice with
PBS followed by RPMI medium containing 10% Fetal Bovine
Serum (FBS), before cryopreserved in 10%DMSO and stored
in liquid nitrogen storage tank. 5mL of blood was donated
from a healthy volunteer as control. The PBMCs and plasma
were processed and stored as described above. The date of
diagnosis, blood sampling, PBMCs cryopreservation, and
EBV immortalization are shown in Supplementary Materials
(available here).
2.2. Blood Test and Disease Activity Calculation. Blood test
result (anti-CCP, RF, ESR, and CRP), tender joint count
(TJC), swollen joint count (SJC), and patient global assess-
ment (PtGA) scores of RA patients were retrieved from the
rheumatologist’s clinic. DAS28-CRP as the indices for disease
activity measurement were calculated using the formula
(0.56∗sqrt(TJC28) + 0.28∗sqrt(SJC28) + 0.36∗ln(CRP+1) +
0.014∗PtGA + 0.96) [13]. The disease activity was classified
into remission (<2.6), low (2.6 - 3.1), moderate (3.2 - 5.1), and
high (>5.1).
2.3. EBV Immortalization. B95-8 marmoset-derived EBV
supernatant was a kind gift from Dr. Alan Soo-Beng Khoo,
Molecular Pathology unit, Institute for Medical Research
(IMR), Malaysia. B-cells from the patient’s peripheral blood
were immortalized using the concentrated EBV supernatant
as previously described [14]. The table in Supplementary
Materials shows the date of PBMC isolation and cryopreser-
vation, LCLs establishment, and duration of cryopreserved
PBMCs stored in liquid nitrogen storage tank. Briefly, a vial
of previously cryopreserved PBMC was thawed out and the
cell number was determined. The cells were adjusted to 2 x
106/mL using freshly thawed EBV supernatant and incubated
overnight at 37∘C, 5% CO
2
in a standing T25 flask. The
next day, transformation medium (RPMI 1640 + 20% FBS
+ 200ng/ml cyclosporine) was added into the flask. The
EBV-infected cells were observed under the microscope to
look for rosette-like transformed LCLs in clusters. LCLs in
passages 3–6 were used for the flow cytometry analysis and
cell proliferation assay.
2.4. Flow Cytometry Analysis. Three-colour cytometry was
performed on FACSCalibur flow cytometer (Becton Dickin-
son) using monoclonal antibodies identifying surface anti-
gens for T-cells (CD3/PE, clone SK7), B-cells (CD19/BB515,
HIB19), and B-cell subsets (CD23/APC, clone EBV-CS5, and
CD27/PE, clone L128). Cell viability solution 7AAD (VIA-
PROBE) was purchased to determine the cell viability. All
antibodies were purchased from Becton Dickinson. Briefly,
cryopreserved PBMCswere thawed and resuspended in 50𝜇L
of BSA stain buffer (Becton Dickinson) and incubated at
room temperature in the dark with prediluted fluorochrome-
conjugated antibodies for 30 minutes. The PBMCs were then
washed twice with BSA stain buffer and resuspended in
500𝜇L of BSA buffer for flow cytometry analysis. Control
PBMC suspensions were prepared with the same proce-
dure. 20,000 viable cells determined by the cell viability
dye were gated and collected for three-colour analysis at
sets of CD3/CD19/CD23 and CD19/CD27/CD23. Data were
analysed using CellQuest Pro software (Becton Dickinson).
2.5. LCLs Proliferation Assay. To separate the LCLs into two
categories (fast- and slow-growing), the cell proliferation rate
was determined using RealTime-Glo MT cell viability assay
(Promega) following the manufacturer’s instruction. This is a
nonlytic luminescence-based assay that can detect real-time
proliferation of live cells in culture up to 72 hours. Briefly,
10,000 cells/well were seeded onto a white flat-bottom 96-
well plate (Greiner Bio-one) in triplicate. 2X reaction mix
was prepared from the provided kit and added to each well.
Cells were incubated at 37∘C, 5% CO
2
for 1 hour before the
measurement was taken at different time points (0, 16, 20,
24, 40, 44, 48, 64, 68, and 72 hours) using a luminescence
microplate reader (Tecan). The relative luminescence units
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(RLUs) versus time graph were plotted to show the growth
curve of the LCLs. In this graph, the cell number was
represented by the RLUs. Using the RLUs, the doubling time
(time required for a cell number to double in value) of each
category of LCLs was calculated using a multipoint online
calculator which were used for significance tests [15]. This
online tool uses the least squares fitting exponential method
to calculate the doubling time [15]. The growth rate (number
of doublings that occur per unit of time) was then calculated
using the formula below:
Growth rate = ln (2)
doubling time (1)
The mean value of all LCLs’ doubling time was 54.69 hours.
Hence, this value was used as the cutoff and LCLs with
doubling time higher than 54.69 hours were grouped into
slow-growing LCLs and vice versa for fast-growing LCLs.
2.6. Statistical Analysis. Flow cytometry analysis was per-
formed in three independent experiments for each category
of LCLs, unless otherwise specified. Data were expressed in
mean values ± standard deviations (std. dev). Significance
was determined using nonparametric tests (Mann-Whitney
and Kruskal-Wallis H) in which the data is considered
significant when p is less than 0.05.
3. Results and Discussion
3.1. Disease Activity of Study Subjects. Table 1 shows the
demographic data of the sixteen RA patients and a healthy
individual and their blood test results of commonly used RA
diagnostic markers indicating their disease activities. Based
on theDAS28-CRP index of 16RApatients, 3 of these patients
were classified as high disease activity, 8 as moderate activity,
3 as remission, and the remaining two as unknown status due
to incomplete data collection.
3.2. Generation of LCLs. PBMCs were harvested from the
sixteen RA patients and one healthy donor (labelled as
C) (Table 1) and cryopreserved. Aliquots of cryopreserved
PBMCs were then used for EBV infection. Out of the
seventeen flasks, 15 EBV-transformed LCLs (except 4E and
14A) were generated one week after infection in which visible
cell clusterswere seen from the flasks.When visualized under
microscope, the LCLs showed typical rosette morphology
with various sizes as indicated by the red arrows (Figure 1).
The success rate of the LCLs generation was 88.23% (15 out of
17).
3.3. Growth Rate and Doubling Time Calculation of Gen-
erated LCLs. We then determined the growth rate of each
generated category of LCLs using a nonlytic and real-time
luminescence-based cell proliferation assay. Figure 2 shows
the growth curve of each category of LCLs represented by
the relative luminescence units (RLUs). Table 2 shows the
calculated doubling time and growth rate of respective LCLs
using an online calculator [15]. From the obtained doubling
148m
167m
66m
Figure 1: Microscopic examination of PBMC-derived EBV-
immortalized B-cells from a RA patient 8A one week after infection.
These immortalized cells are annotated as LCL-8A. Red arrows show
the rosette-like EBV-immortalized LCLs at 4x (upper panel), 10x
(middle panel), and 20x (bottom panel) magnifications. Scale bars
are indicated in yellow.
time of each category of LCLs, we divide the LCLs into two
categories using 54.69 hours (mean value of all LCLs) as the
cut-off value, which resulted in 10 fast-growing and 5 slow-
growing LCLs (Tables 2 and 4) (p<0.05).
3.4. Surface Marker Expression of LCLs. PBMCs and corre-
sponding LCLs were subjected to flow cytometry analysis to
determine their surface marker expression including CD3,
CD19, CD23, and CD27. CD3 and CD19 are surface markers
for T-cells and B-cells, respectively. Using the PBMCs isolated
from patient 8A and the corresponding LCL-8A as examples,
Figure 3 shows how the CD3+ T-cells and CD19+ B-cells were
profiled and gated by flow cytometry. The expression level
was then presented in percentage from the total number
of analysed lymphocytes which were 20,000 cells. In the
donors’ PBMCs, 29.78-81.8% were T-cells while 2.35-45.95%
comprise B-cells. Following the EBV transformation, T-cell
populations reduced to 0-0.27% while B-cell populations
increased to 68.59-89.35%. This clearly indicates the success
of B-cell immortalization by EBV which has taken over
the T-cell population. CD3+ T-cells senesced and would be
completely washed off from the LCLs.
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Figure 2: Growth curves of LCLs. Relative luminescence units represent the viability signals of cells at various time points. The filled lines
represent the fast-growing LCLs whereas dotted lines represent the slow-growing LCLs.
Table 2: Doubling time and growth rate of LCLs.
Sample Doubling time (hour) Growth rate Category
1B 47.16 0.0147 Fast
2C 31.69 0.0219 Fast
5B 36.05 0.0192 Fast
6A 107.32 0.0065 Slow
7B 41.4 0.0167 Fast
8A 39.69 0.0175 Fast
9D 25.92 0.0267 Fast
10E 44.57 0.0156 Fast
11A 42.48 0.0163 Fast
12A 73.59 0.0094 Slow
13B 48.74 0.0142 Fast
15A 64.14 0.0108 Slow
16A 84.93 0.0082 Slow
17A 78.53 0.0088 Slow
C 54.2 0.0128 Fast
CD23 is a B-cell activationmarkerwhile CD27 is amarker
for memory B-cells [16, 17]. In RA patients, elevated levels
of CD23-expressing B-cells have been previously reported
to positively correlate with the disease activity, and they
could potentially serve as a therapeutic target [10, 18]. In
contrast, CD27+ B-cells were found to negatively correlate
with disease activity and found to be impaired in RA patients
[12]. In the current study, we could not differentiate the
expression pattern of CD23 and CD27 in PBMCs and LCLs
(Table 3). Figure 4 depicts the gating of CD19+, CD23+,
and CD27+ from the PBMCs isolated from patient 8A and
the corresponding LCL-8A by flow cytometry. From all
LCLs, while 68.59-89.35% were CD19+ as expected, they
exhibit expression of CD23 (16.94-58.9%) and CD27 (15.74-
80.89%). B-cells coexpressing CD23 and CD27 were 5.72-
41.53% (Table 3).
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Figure 3: T-cell (CD3) and B-cell (CD19) surface marker profiling by flow cytometry. The upper panel shows the analysis of PBMCs isolated
from patient 8A while the lower panel shows the analysis of the corresponding LCLs (LCL-8A). R1: 7AAD− live cells; R2: gated lymphocytes;
R3: gated CD3+ T-cells; R4: gated CD19+ B-cells.
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Figure 4: CD23 and CD27 expression analysis of CD19+ B-cells by flow cytometry. The upper panel shows the analysis of PBMCs isolated
from patient 8A while the lower panel shows the analysis of the corresponding LCLs (LCL-8A). R3: gated CD27+ cells; R4: gated CD19+
B-cells; R5: gated CD19+CD23+; R6: gated CD23+CD27+ cells; R7: gated CD19+CD27+ cells; R8: gated CD19+CD23+CD27+ cells.
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Table 3: Surface marker expression of PBMCs and LCLs derived from participated subjects.
Sample type and annotation Surface marker expression (%) ± standard deviation
CD3+ CD19+ CD19+CD23+ CD19+CD27+ CD19+CD23+CD27+
1B PBMC-1B 66.58 5.62 3.92 0.36 0.01
LCL-1B 0.02 81.19 ± 0.77 49.26 ± 1.26 17.75 ± 1.51 6.63 ± 0.93
2C PBMC-2C 78.72 6.07 5.57 1.56 0.41
LCL-2C 0.06 ± 0.03 86.61 ± 0.38 39.57 ± 0.25 53.66 ± 0.56 20.59 ± 0.31
5B PBMC-5B 44.10 14.02 7.97 3.73 0.25
LCL-5B 0.09 ± 0.05 79.47 ± 0.31 38.52 ± 0.16 51.5 ± 1.03 19.09 ± 0.68
6A# PBMC-6A - 19.4 19.5 3.7 1.0
LCL-6A# - 77.4 27.4 39.7 11.06
7B PBMC-7B 72.27 10.95 8.70 1.49 0.22
LCL-7B 0.01 ± 0.02 80.58 ± 1.28 48.06 ± 1.29 23.34 ± 5.76 8.79 ± 3.13
8A PBMC-8A 66.6 16.2 17.9 2.34 1.24
LCL-8A 0.14 ± 0.21 86.0 ± 0.83 58.9 ± 2.58 34.4 ± 4.90 17.6 ± 1.37
9D PBMC-9D 49.57 2.56 2.06 0.18 0.03
LCL-9D 0.02 ± 0.01 71.32 ± 0.87 43.17 ± 0.70 15.74 ± 0.28 5.72 ± 0.22
10E PBMC-10E 34.15 23.58 22.57 3.89 0.64
LCL-10E 0 76.59 ± 0.51 44.72 ± 0.24 43.94 ± 0.03 19.54 ± 0.18
11A PBMC-11A 59.45 13.02 8.75 3.74 0.57
LCL-11A 0.05 ± 0.01 68.59 ± 0.73 16.94 ± 0.37 48.83 ± 1.10 8.89 ± 0.30
12A PBMC-12A 48.27 9.10 7.58 5.42 0.53
LCL-12A 0.05 ± 0.01 72.70 ± 1.20 18.29 ± 0.40 51.64 ± 1.11 9.73 ± 0.21
13B PBMC-13B 29.78 45.95 13.61 1.65 0.10
LCL-13B 0.01 + 0.01 74.95 + 1.42 52.87 + 1.54 20.18 + 1.51 12.74 + 1.2
15A PBMC-15A 10.46 2.35 1.93 1.12 0.11
LCL-15A 0 88.84 + 1.72 19.47 + 0.46 80.89 + 0.82 17.78 + 0.49
16A PBMC-16A 81.8 9.66 9.74 2.66 0.82
LCL-16A 0.27 ± 0.41 72.8 ± 0.64 43.7 ± 1.81 50.6 ± 8.63 26.0 ± 3.05
17A PBMC-17A 69.28 11.64 10.66 3.39 0.61
LCL-17A 0 89.35 + 1.03 41.15 + 2.07 80.06 + 1.59 41.53 + 0.65
C PBMC-C 75.5 16.3 15.4 1.85 0.59
LCL-C 0.10 ± 0.14 70.6 ± 1.73 44.1 ± 4.04 37.9 ± 0.24 17.6 ± 1.80
LCL: lymphoblastoid cell line; PBMC: peripheral bloodmononuclear cell.
#Flow cytometric analysis for all surface markers was only performed once and CD3 levels were not determined due to the limitation of cell number.
Table 4: Statistical analysis of CD23, CD27, and CD23CD27 expression of fast- and slow-growing LCLs.
Category Doubling time Growth rate CD23 (%) CD27 (%) CD23 CD27 (%)
mean p value mean p value mean p value mean p value mean p value
Fast (n – 10) 38.62 0.001 0.0186 0.001 42.39 0.075 36.15 0.028 13.36 0.241
Slow (n – 5) 73.06 0.0101 35.28 51.57 19.49
3.5. Correlation of Disease Activity, Surface Marker Expres-
sion Level, and LCL Proliferation. A statistical analysis
was performed to test the correlation between the disease
activity and surface marker expressions; however, none of
them showed significance. Similarly, the disease activity
did not correlate with the growth rate of corresponding
LCLs.
From the doubling time of each category of LCLs, mean
values for both fast- and slow-growing LCLs were deter-
mined and subjected to statistical analysis. Table 4 shows
a significant difference (p<0.05) in terms of doubling time
between the two categories. Similarly, the mean values of the
CD23, CD27, and CD23+CD27+ levels of the respective cat-
egory were determined. The fast-growing LCLs have higher
expression of CD23 (42.39%) compared to the slow-growing
LCLs (35.28%). However, this is not statistically significant
(Table 4). Inversely, CD27 expression and CD23/CD27 coex-
pression were lower in the fast-growing LCLs (36.15 and
13.36%, respectively) compared to the slow-growing LCLs
(51.57% and 19.49%, respectively). When a statistical analysis
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is performed, only the fast-growing LCLs show significantly
lower in CD27 but not CD23/CD27 expression. Further
studies with larger sample size are required to validate these
findings.
The high expression of CD23 might be due to the
EBV infection or transformation. There is evidence show-
ing that B-cell immortalization might rely on the cel-
lular CD23 expression. The study showed that CD23-
negative B-cells could be infected by EBV but could
not be immortalized unless supplementing with specific
growth factors [19]. Another study showed that EBV-infected
B-cells could develop into two distinct subpopulations:
CD23highCD58+IL6− and CD23lowCD58+IL6+ [20]. The for-
mer B-cell subpopulation actively proliferated while the latter
subpopulation ceased to proliferate. The expression of CD23
might also be induced by EBV nuclear antigen 2 (EBNA-2)
expression following the EBV transformation of B-cells as
previously described in a Burkitt lymphoma (BL) cell line
[16]. In contrast, the higher expression of CD27 in slow-
growing LCLs may suggest their inhibitory effects on the
LCLs' proliferation.
4. Conclusions
CD23 could play a stimulatory role in EBV transformation
of B-cells and the LCLs’ growth. Our studies showed that
the fast-growing LCLs exhibited higher CD23 expression and
lower CD27 expression and CD23CD27 expression. Further
studies with a larger sample size are warranted to investigate
in depth on the implication of the surface marker expression
on the EBV maintenance and cellular growth.
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